Secondary Tumors of the Urinary System: An Imaging Conundrum

Ali Devrim Karaosmanoglu, MD, Mehmet Ruhi Onur, MD, Musturay Karcaaltincaba, MD, Deniz Akata, MD, Mustafa Nasuh Ozmen, MD

All authors: Department of Radiology, Hacettepe University, School of Medicine, Ankara 06230, Turkey

Imaging features of metastases to the urinary system may closely mimic primary urinary tract tumors, and differential diagnosis by imaging alone may be problematic or even impossible in some cases. The main purpose of this article was to familiarize radiologists with imaging findings of metastasis to the urinary system on cross-sectional imaging, with an emphasis on abdominal and pelvic computed tomography and magnetic resonance imaging. In addition, we review the clinical importance and implications of metastases to the urinary tract and provide information on diagnostic work-ups.

Keywords: Urinary system; Metastasis; Kidney; Ureter; Bladder; Urethra; CT; MRI

INTRODUCTION

The urinary tract may be involved in metastatic spread from other primary cancers. Information on imaging features of secondary urinary tract tumors is very limited and mostly based on anecdotal case reports. A variety of tumors may metastasize to the urinary tract and may present, mostly, with vague and non-specific imaging features. Breast cancer, malignant melanoma, lung cancer, head and neck malignancies, thyroid tumors, colorectal and pancreatic cancers, bone and soft tissue sarcomas, and Merkel cell carcinoma may metastasize to the urinary tract (1-3).

The imaging features of secondary urinary tract tumors have not been very well described in the relevant literature, the findings are almost always non-specific, and diagnosis is mostly based on either tissue diagnosis or clinical history. It is not unwise to consider the occurrence of secondary urinary tract tumors in patients with advanced malignancy, but it should also be noted that metastasis to the urinary system may also be the first sign of detectable distant metastasis from an unrelated source (1).

The timely recognition of secondary urinary tract tumors with ultrasonography (US), computed tomography (CT), and magnetic resonance imaging (MRI) is of paramount importance. As the outcome and treatment approaches to primary and secondary urinary tumors may vary significantly, prompt detection and differentiation have the potential to dramatically affect the clinical management. While the main approach to primary tumors is potentially curative surgery, in patients with secondary urinary tumors, surgical intervention can be deferred or may be performed in selected patients.

Renal Metastasis

Metastasis to the kidney is not uncommon, occurring between 7% and 12% of patients with overall cancers at post-mortem examination (4, 5). The actual detection...
Secondary Tumors of the Urinary System

rate is lower in clinical settings than autopsy data, as the post-mortem studies also include microscopic metastatic involvement, which is generally beyond the resolution of cross-sectional imaging modalities (6). A recent study showed the imaging incidence of metastases to the kidney to be 0.9% (7).

The detection of metastasis in the kidneys is usually a sign of advanced disease and almost always a grave prognosis. The primary site can be almost anywhere in the body, but the most common primary sites are lung, breast, skin (melanoma), and gastrointestinal tract, with lung being the most common (4-6, 8). Although renal metastases from extrarenal malignancies usually present with bilateral involvement, unilateral solitary metastasis may also occur. Hematogenous renal metastases from lung, breast, gastrointestinal tract, and hematologic malignancies and malignant melanoma tend to give rise to bilateral, multiple renal masses, while lung cancer and melanoma may also metastasize via lymphangitic spread, which may result in unilateral perirenal and renal involvement (8, 9).

Despite being extremely rare, it should be noted that in a small percentage of oncologic patients with non-renal malignancy, kidneys may be the only site of metastasis (10). The detection of these patients with solitary metastases is extremely important as these patients may benefit from surgical intervention (11). These solitary metastases are generally clinically silent and discovered during follow-up studies; however, local symptoms like hematuria may also be detected in small percentage of patients (11). These metastatic deposits occur due to hematogenous spread and present as cortical nodules, which likely represent the entrapment of the metastatic cells in glomerular capillary tufts (12). As uroepithelium is not typically involved, hematuria, even in patients with large masses, is rare (13). The mean duration between the diagnosis of a primary extrarenal tumor and renal metastasis is highly variable, but the mean interval time has been reported to be 2.2 years (8).

The data on the imaging findings of metastases to the kidneys is sparse. The distinction between primary kidney tumors and metastases to the kidneys is of crucial importance as the treatment approaches to these two different clinical entities may be almost completely different.

Although US has been reported as a useful tool for diagnosing renal metastases, it has several limitations (8, 14). Small lesions (1−2 cm) and lesions with similar echotexture to the background renal parenchyma may be hard to discern with US. When detected by US, they appear as homogenous hypoechoic masses without increased through transmission; however, heterogenous or echogenic metastases have also been reported (Fig. 1) (8, 14).

CT is generally the most commonly utilized imaging tool in the imaging follow-up of the abdomen in patients with known malignancy. CT, with its well-known clinical robustness, can also evaluate other sites in the abdomen in addition to the kidneys and may give a better picture of the full extent of tumor load in the abdomen. The CT appearances of renal metastases are mostly non-specific (15). On contrast-enhanced CT, most metastases have been reported to appear as endophytic, ill-defined, small, solid lesions with homogeneous enhancement (Fig. 2) (7). They are typically multifocal and do not distort the kidney contours. They typically enhance less than the background renal parenchyma and mostly appear as either isodense or slightly hypodense (10−40 Hounsfield units [HU]) on unenhanced CT studies (Fig. 3) (16). After contrast agent

Fig. 1. 75-year-old female patient with known breast cancer with recently detected pulmonary and bone metastases was referred for restaging after chemotherapy.

A. Gray-scale US image demonstrates mildly hyperechoic mass (arrows) in lower pole of left kidney. Lesion is hardly discernible from background renal parenchyma on US image. B, C. Axial and coronal contrast-enhanced CT images reveal infiltrative-type hypodense solid mass (arrows) with relatively less enhancement as compared to background renal parenchyma. CT = computed tomography, US = ultrasonography
administration, they tend to mildly enhance (5–15 HU) compared to non-contrast images (15). Multifocality and bilaterality are other helpful clues for diagnosis (17). Metastatic deposits are mostly completely surrounded by renal parenchyma and rarely appear as an exophytic lesion (Fig. 4) (18). Calcification may also be detected within the renal metastases. The underlying reasons for calcification include either secretions from the tumor cells (mucoid and papillary carcinomas) or cellular differentiation (osteosarcoma and chondrosarcomas) (19). Patel et al. (7) suggested that possibility of renal metastasis in the setting of a renal mass increases when the extrarenal malignancy has a higher stage. In their study, solid nature and endophytic location were significantly higher in renal metastases than primary renal tumors in patients with extrarenal malignancy (7).

Not much has been published about the imaging findings of renal metastases on MRI. These lesions are generally hypointense compared to background renal parenchyma on T1-weighted images (T1WI) while heterogeneously hyperintense on T2-weighted images (T2WI). They mostly hypoenhance after contrast injection. Diffusion-weighted imaging (DWI) may help detection and characterization of kidney lesions (20). Renal metastases present with increased signal intensity on DWIs and decreased signal on apparent diffusion coefficient maps secondary to restricted diffusion of water molecules (Fig. 5) (21).

Renal cell cancer (RCC) is the main differential diagnosis, and differentiation may not be possible, especially in patients with solitary metastases. The most common
subtype of RCC is a clear cell variant that is characterized by its high vascularity, which is an uncommon feature in renal metastases. The relatively hypovascular variants of RCC, such as papillary type, are also well known, and differentiation from metastasis may be difficult or even impossible in some patients. Hypointensity of papillary type RCC may be helpful for differential diagnosis as the metastatic renal masses are typically hyperintense on T2WIs (9). The infiltration of renal veins and inferior vena cava is also a probable indicator of RCC rather than a metastasis.

Fig. 4. 66-year-old male patient with known lung cancer and chest wall invasion. No distant metastasis was known at time of this CT scan. Axial (A) and coronal (B) contrast-enhanced CT images reveal low-attenuating, exophytic mass (arrows) that was histopathologically proven to be metastasis from lung carcinoma.

Fig. 5. 74-year-old female patient with known lung cancer and metastatic involvement of left iliac bone. Patient was in clinical remission for two years after last treatment. A. Axial fat-saturated T2WI reveals hypointense, focal parenchymal mass (arrow) in subcortical part of right kidney. B. Corresponding DWI sequence image shows intense diffuse restriction at location of mass (arrow). Patient refused percutaneous biopsy at that point, and she was placed on close imaging surveillance. C. Axial fat-saturated T2WI obtained 3 months after first scan revealed interval enlargement of lesion (arrow). D. Corresponding DWI clearly demonstrates focally increased signal suggestive of diffusion restriction (arrow). Percutaneous biopsy confirmed metastatic nature of this lesion. E. Apparent diffusion coefficient map confirms true diffusion restriction by demonstrating significant hypointensity at site of lesion (arrow). DWI = diffusion-weighted imaging, T2WI = T2-weighted image
An infiltrative pattern similar to renal metastasis can also be detected in sarcomatoid RCC variants, primary uroepithelial tumors, and primary renal lymphoproliferative disorders (19). A comparison of imaging features of RCC and renal metastases is presented in Table 1.

Metastases to the renal collecting system occur less frequently than renal parenchymal metastases. Imaging differentiation between uroepithelial metastases and primary urothelial tumors may be difficult, as both may appear as diffuse urothelial thickening or as a fungating exophytic mass (Fig. 6) (9).

Metastasis to Perirenal Space

The perirenal space is a well-defined and well-known anatomical compartment that is located in the retroperitoneum. Anatomically, it is limited mainly by anterior and posterior pararenal spaces. It is bounded anteriorly by the anterior renal fascia (also called Gerota’s fascia) and posteriorly by the posterior renal fascia (also called Zuckerkandl’s fascia). These fasciae fuse laterally and form the lateroconal fascia. Within this anatomical compartment lie the kidneys, the proximal ureter, perirenal fat, the adrenal glands, bridging connective tissue, and several vessels (22). The left and right perirenal spaces communicate with each other at the midline and with the pelvic retroperitoneal spaces below the iliac fossa (23).

Lung cancer, malignant melanoma, breast carcinoma, and prostate cancer may metastasize to the perirenal space (24, 25). The main underlying reason for the peculiar tendency of lung cancer to metastasize to the perirenal space is the connections between the perirenal and mediastinal lymphatic vessels (25, 26). Infiltrative-type renal metastasis may also invade perirenal space (8).

On cross-sectional imaging, the lesions often appear as several solid lesions around the kidneys (Fig. 7) (24, 27).

| Imaging Features           | Renal Cell Cancer (Clear Cell Type) | Metastasis                              |
|----------------------------|-------------------------------------|-----------------------------------------|
| Involvement                | Unilateral                          | Bilateral                               |
| Localization               | Cortex                              | Cortex, medulla or rarely renal pelvis  |
| Size                       | Large                               | Small                                   |
| Growth pattern             | Ball-type                            | Ball- or bean-type                      |
| Infiltrative               | 5%                                  | Common                                  |
| Calcification              | 30%                                 | Uncommon                                |
| Contour                    | Smooth or lobulated                  | Irregular                               |
| Multicentricity            | Uncommon                             | Common                                  |
| Vascularity                | Hypervascular                       | Less vascular                           |
| Central necrosis           | Common                              | Uncommon                                |
| Venous involvement         | Common                              | Rare                                    |

Fig. 6. 64-year-old female with known breast cancer and multiple metastases in liver. A. Axial contrast-enhanced CT reveals nodular wall thickening in left renal pelvis (arrow) with intense contrast enhancement. Also note multiple metastases in liver. B. Axial post-contrast T1-weighted image also demonstrates abnormal irregular wall thickening (arrow) with associated brisk contrast enhancement. Urine cytology confirmed uroepithelial metastasis.
The enhancement patterns of these metastatic deposits may differ based on the primary source. Lung and prostate cancers typically hypoenhance during arterial phase; melanoma and breast metastases show brisk arterial enhancement and portal venous phase wash-out (22). Breast cancer metastases may appear infiltrative, which makes them difficult to differentiate from lymphomas from a morphological standpoint. However, brisk enhancement of breast cancer metastases may allow differential diagnosis (22). Based on our experience, primary tumors involving the perirenal areas are rare, except for retroperitoneal mesenchymal tumors. Multifocality of the perirenal lesions may also suggest a secondary process rather than a primary one.

**Ureteral Metastasis**

Ureters are most commonly affected by tumor extension from adjacent organs, and these involvements should be differentiated from true hematogenous and lymphatic
metastases. Transmural infiltration, or less commonly, diffuse infiltration of the local mucosa with or without muscular layer involvement, may be observed in cases of hematogenous and lymphatic metastases (Fig. 8) (28). This true metastatic involvement of the ureters is an uncommon clinical situation and a very rare cause of ureteral obstruction (29, 30). Since its first description in 1909, only around 400 cases have been reported (29, 31, 32). Autopsy studies have also revealed only rare occurrences of ureteral metastases, and in a series of 10233 consecutive autopsies, the incidence of ureteral metastasis was only 0.37% (33). As the ureters do not have a continuous longitudinal network of lymphatic and blood vessels, they are relatively resistant to metastasis by these two routes (34).

Despite the fact that most of the ureteric metastases are asymptomatic and incidentally diagnosed at autopsy, urinary obstruction may also occur (1, 35, 36). The breast and gastrointestinal systems comprise half of the cases, followed by prostate and uterine cancers comprising 30–40%, with gastric and lung cancers making up the remaining cases (1). Ureters may be involved in partial or full thickness (37, 38). As the periureteral adventitia is rich in blood vessels, this part of the ureter is generally the first layer involved (1).

From an imaging standpoint, the differentiation of ureteral metastasis from primary urothelial tumors might be difficult or even impossible. In our clinical practice, primary uroepithelial tumors of the ureter typically involve a long segment and demonstrate multifocality, whereas secondary tumors usually affect a relatively short segment. Clinical history may also help differential diagnosis as some tumors are more prone to uroepithelial metastasis than others. The detection of asymmetric wall enhancement, wall thickening, and urinary obstruction are the expected imaging findings. Strictures after stone passage, distal ureteral stenosis due to tuberculosis, amyloidosis, and endometriosis should be considered in the differential diagnosis (Fig. 9). Endoscopic evaluation of the ureters with histopathologic evaluation may be required in most of the cases.

**Metastasis to Urinary Bladder**

Secondary tumors of the urinary bladder are rare and comprise less than 2% of all bladder cancers (2, 39). The most common primary sources are stomach, breast, and colon cancer and melanoma. Urinary bladder metastases from a primary RCC are rare, with fewer than 40 reported cases in the medical literature, with neck and trigone the most commonly involved sites (2, 40). The metastases may be clinically silent or may present with hematuria. The patients diagnosed with bladder metastasis are generally at an advanced stage, and the prognosis is usually dismal; however, in very rare instances, the bladder may be the only metastatic site (41).

Imaging mostly displays polypoid or non-polypoid diffuse asymmetric wall thickening (Figs. 10, 11). Proper imaging technique is important for both the diagnosis and adequate staging. Differentiation of bladder metastases from primary bladder tumors may be difficult from an imaging standpoint, and pathological diagnosis is almost always indicated.

**Urethral Metastasis**

Urethral metastases are extremely rare, but occur more

---

**Fig. 9.** 64-year-old female with known breast cancer who was in clinical remission for last 5 years. She was referred for annual follow-up CT and was asymptomatic at time of scan.  
**A.** Axial venous phase scan demonstrates moderate-severe hydroureteronephrosis (arrow), with significant loss of renal parenchyma, on left kidney. **B.** Axial venous phase scan demonstrates faint enhancement of lower left ureter (arrow). This was transition point of left dilated ureter. **C.** Enhancement becomes more pronounced on urographic phase image (arrow). Endo-urologic biopsy confirmed non-neoplastic cells but amyloid deposit.
Secondary Tumors of the Urinary System

Metastasis to the urethra most commonly results from prostate, bladder, lung, and colorectal cancers (42, 43). Urethral and penile metastases may result from hematogenous involvement, instrumental spread, retrograde lymphatic spread, and direct extension. Retrograde lymphatic spread was reported to be responsible especially for metastasis from colon cancers (42). Superficial US performed with a linear probe can detect metastasis in the urethra. Abundant secondary tumoral involvement of urethra presents as solid nodular or cylindrical mass with heterogeneous contrast-enhancement (Fig. 12). Superior soft-tissue resolution makes MRI a preferred imaging modality in assessment of secondary tumors of the urethra in terms of location, size, and local extension. Differentiation between primary urethral cancers and secondary urethral extension of adjacent malignancies such as rectal, vaginal, and cervical tumors can be accomplished with MRI.

The Role of Percutaneous Biopsy in Diagnosis

The urinary system is frequently the site of percutaneous biopsies, and the kidneys are the most frequently biopsied organs. Adequate pre-procedural imaging and patient work-up is of utmost importance (44). The probability of a renal mass being a metastasis in patients with extrarenal malignancy is almost equal to the likelihood of its being a primary renal tumor (7). Since imaging features of

---

**Fig. 10.** 61-year-old female with known RCC and retroperitoneal lymph node metastases presenting with hematuria. 
A. Axial contrast-enhanced CT image demonstrates polypoid lesion located close to left ureteral orifice (arrow). There was no evidence of hydronephrosis in left kidney on upper level images (not shown). B. Axial urographic phase image clearly shows filling defect (arrow) created by same polypoid lesion. Cystoscopic biopsy confirmed metastatic RCC. RCC = renal cell cancer

**Fig. 11.** Bladder metastasis in 74-year-old female with known breast cancer, which was last treated 10 years ago; she was in clinical and imaging remission since then. She recently presented with polyuria and gross hematuria. 
A. Bilateral dilatation of renal collecting system is seen on axial contrast-enhanced CT image. B. Axial contrast-enhanced CT image demonstrates asymmetric thickening (arrows) in left lateral wall of bladder. Chest CT was also negative. Cystoscopic biopsy confirmed metastatic breast cancer.
Urinary system metastases cannot exclude the possibility of a primary tumor of the urinary system, histopathologic examination of renal masses in patients with an extra-urinary malignancy is necessary in the management of and the decisions regarding the treatment options of these patients (3, 7, 10, 40). The percutaneous biopsy of solid renal and perirenal lesions are generally straightforward, but cystic lesions may deserve further attention, as the biopsy yields may be lower in these lesions (45). Targeting the solid parts of patients’ cystic lesions may be more helpful in the diagnosis of semisolid renal and perirenal lesions (44).

Bladder lesions may also be diagnosed with percutaneous biopsy. This approach may be even more important in patients who have difficulties with retrograde endourological procedures due to urethral stenosis (46).

CONCLUSION

Metastasis to the urinary system in patients with non-urinary system primary tumors is a relatively rare clinical phenomenon. Early diagnosis and evaluation of these subjects is important to obtain a satisfactory patient outcome. Given the ever-increasing role of cross-sectional imaging in the oncologic patient population, it would not be irrational to predict that this diagnosis will be more commonly made in the near future.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

REFERENCES

1. Arvind NK, Singh O, Gupta S, Ali Q. Ureteral metastasis as the presenting manifestation of pancreatic carcinoma. Rev Urol 2013;15:124-130
2. Doo SW, Kim WB, Kim BK, Yang WJ, Yoon JH, Jin SY, et al. Metastasis of renal cell carcinoma to the bladder. Korean J Urol 2013;54:69-72
3. Zhou C, Urbauer DL, Fellman BM, Tamboli P, Zhang M, Matin SF, et al. Metastases to the kidney: a comprehensive analysis of 151 patients from a tertiary referral centre. BJU Int 2016;117:775-782
4. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950;3:74-85
5. Bracken RB, Chica G, Johnson DE, Luna M. Secondary renal neoplasms: an autopsy study. South Med J 1979;72:806-807
6. Bates AW, Baithun SI. The significance of secondary neoplasms of the urinary and male genital tract. Virchows Arch 2002;440:640-647
7. Patel U, Ramachandran N, Halls J, Parthipun A, Slide C. Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT. AJR Am J Roentgenol 2011;197:W680-W686
8. Choyke PL, White EM, Zeman RK, Jaffe MH, Clark LR. Renal metastases: clinicopathologic and radiologic correlation. Radiology 1987;162:359-363
9. Prasad SR, Dalrymple NC, Surabhi VR. Cross-sectional imaging
Secondary Tumors of the Urinary System

evaluation of renal masses. Radiol Clin North Am 2008;46:95-111, vi-vii
10. Sánchez-Ortiz RF, Madsen LT, Bermejo CE, Wen S, Shen Y, Swanson DA, et al. A renal mass in the setting of a nonrenal malignancy: when is a renal tumor biopsy appropriate? Cancer 2004;101:2195-2201
11. Adamy A, Von Bodman C, Ghoneim T, Favaretto RL, Bernstein M, Russo P. Solitary, isolated metastatic disease to the kidney: Memorial Sloan-Kettering Cancer Center experience. BJU Int 2011;108:338-342
12. Olsson CA, Moyer JD, Laferte RO. Pulmonary cancer metastatic to the kidney—-a common renal neoplasm. J Urol 1971;105:492-496
13. Klinger ME. Secondary tumors of the genito-urinary tract. J Urol 1951;65:144-153
14. Mitnick JS, Bosniak MA, Rothberg M, Megibow AJ, Raghwendra BN, Subramanyam BR. Metastatic neoplasm to the kidney studied by computed tomography and sonography. J Comput Assist Tomogr 1985;9:43-49
15. Bailey JE, Roubidoux MA, Dunnick NR. Secondary renal neoplasms. Abdom Imaging 1998;23:266-274
16. Bhatt GM, Bernardino ME, Graham SD Jr. CT diagnosis of renal metastases. J Comput Assist Tomogr 1983;7:1032-1034
17. Vikram R, Beland MD, Blafox MD, Moreno CC, Gore JJ, Harvin HJ, et al. ACR appropriateness criteria renal cell carcinoma staging. J Am Coll Radiol 2016;13:518-525
18. Sun MR, Pedrosa I. Magnetic resonance imaging of renal masses. Semin Ultrasound CT MR 2009;30:326-351
19. Ferrozzi F, Bova D, Campodonico F. Computed tomography of renal metastases. Semin Ultrasound CT MR 1997;18:115-121
20. Maurer MH, Härmä KH, Thoery H. Diffusion-weighted genitourinary imaging. Radiol Clin North Am 2017;55:393-411
21. Thoery HC, De Keyzer F, Oyen RH, Peeters RR. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: initial experience. Radiology 2005;235:911-917
22. Heller MT, Haarer KA, Thomas E, Thaete FL. Neoplastic and proliferative disorders of the perinephric space. Clin Radiol 2012;67:e31-e41
23. Surabhi VR, Menias C, Prasad SR, Patel AH, Nagar A, Dalrymple NC. Neoplastic and non-neoplastic proliferative disorders of the perirenal space: cross-sectional imaging findings. Radiographics 2008;28:1005-1017
24. Grützner G, Jungblut RM. [Perirenal metastasis of a malignant melanoma in a young child]. Aktuelle Radiol 1993;3:372-374
25. Wilbur AC, Turk JN, Capek V. Perirenal metastases from lung cancer: CT diagnosis. J Comput Assist Tomogr 1992;16:589-591
26. Gore RM, Balfe DM, Aizenstein RI, Silverman PM. The great escape: interfascial decompression planes of the retroperitoneum. AJR Am J Roentgenol 2000;175:363-370
27. Koutani A, Lechevallier E, André M, de Fromont M, Coulangue C. [Contralateral perirenal metastasis of renal adenocarcinoma]. Prog Urol 1997;7:1002-1003
28. Nikolaos F, Panagiotis A, Konstantinos B, Vassiliotis S, Iraklis P. Distant ureteral metastasis from colon adenocarcinoma: report of a case and review of the literature. Case Rep Urol 2014;2014:196425
29. Katsuno G, Kagawa S, Kokudo Y, Muraoka A, Tatemoto A, Sone Y, et al. Ureteral metastasis from appendiceal cancer: report of a case. Surg Today 2005;35:168-171
30. Roy S, Bajjal SS. Pancreatic adenocarcinoma presenting with ureteric metastases. Case report and review of literature. Clin Imaging 1993;17:99-103
31. Haddad FS. Metastasis to the ureter. Review of the world literature, and three new case reports. J Med Liban 1999;47:265-271
32. Stow B. IX. Fibrolymphosarcoma of both ureters metastatic to a primary lymphosarcoma of the anterior mediastinum of thymus origin. Ann Surg 1909;50:901-906
33. Maclean JT, Fowler VB. Pathology of tumors of the renal pelvis and ureter. J Urol 1956;75:384-415
34. Presman D, Ehrlich L. Metastatic tumors of the ureter. J Urol 1948;59:312-325
35. Cohen WM, Freed SZ, Hasson J. Metastatic cancer to the ureter: a review of the literature and case presentations. J Urol 1974;112:188-189
36. Winalski CS, Lipman JC, Tumeh SS. Ureteral neoplasms. Radiographics 1990;10:271-283
37. Fitch WP, Robinson JR, Radwin HW. Metastatic carcinoma of the ureter. Arch Surg 1976;111:874-876
38. Marincek B, Scheidegger JR, Studer UE, Kraft R. Metastatic disease of the ureter: patterns of tumoral spread and radiologic findings. Abdom Imaging 1993;18:88-94
39. Gelister JS, Falzon M, Crawford R, Chappel CR, Hendry WF. Urinary tract metastasis from renal carcinoma. Br J Urol 1992;69:250-252
40. Morichetti D, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, et al. Secondary neoplasms of the urinary system and male genital organs. BJU Int 2009;104:770-776
41. Ramsey J, Beckman EN, Winters JC. Breast cancer metastatic to the urinary bladder. Ochsner J 2008;8:208-212
42. Kazama S, Kitayama J, Sunami E, Niimi A, Nomiya A, Homma Y, et al. Urethral metastasis from a sigmoid colon carcinoma: a quite rare case report and review of the literature. BMC Surg 2014;14:31
43. Cheng CW, Wong WS, Chan LW, Lai FM. A rare cause of acute urinary retention: urethral metastasis from renal cell carcinoma. Int Urol Nephrol 2004;36:145-147
44. Bhagavatula SK, Shyn PB. Image-guided renal interventions. Radiol Clin North Am 2017;55:359-371
45. Rybicki FJ, Shu KM, Cibas ES, Fielding JR, vanSonnenberg E, Silverman SG. Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses. AJR Am J Roentgenol 2003;180:1281-1287
46. Butros SR, McCarthy CJ, Karaosmanoglou AD, Shenoy-Bhangle AS, Arellano RS. Feasibility and effectiveness of image-guided percutaneous biopsy of the urinary bladder. Abdom Imaging 2015;40:1838-1842